ADHD is one of the most common neurodevelopmental conditions, yet its diagnosis still relies almost entirely on symptom checklists that overlook the biological diversity underlying the condition. This session brings together cutting-edge research to explore where ADHD science is headed—from early intervention to brain-based precision care.

We'll begin discussing the role of clinical trials in developing safer, more efficacious treatments for pediatric ADHD, highlighting emerging treatments and unmet needs. We’ll contemplate how rigorous trial design (structured monitoring, ECGs, lab work) can provide the real-world data needed for providers to offer precision treatments.

From there, we'll shift to groundbreaking neurophysiological research using transcranial magnetic stimulation (TMS) to identify distinct ADHD subtypes based on motor cortex activity. This work reveals that children with clinically similar symptom profiles may have very different underlying neurocognitive mechanisms—some driven by motor initiation delays, others by executive functioning deficits, and others by behavioral dysregulation.

Together, these studies point toward a future of precision care: matching treatments to a child's unique neurobiological profile rather than a one-size-fits-all approach. Attendees—including clinicians, therapists, educators, and parents—will leave with a clearer understanding of how targeted treatment and neurocognitive profiling could reshape ADHD diagnosis and care in the years ahead.